No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
TEVA250117P26500
- 0.00
- 0.000.00%
15min DelayClose Jan 27 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest26.50Strike Price0.00Turnover0.00%IV-21.67%PremiumJan 17, 2025Expiry Date4.72Intrinsic Value100Multiplier-10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $28
10 Health Care Stocks With Whale Alerts In Today's Session
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Peering Into Teva Pharmaceutical Indus's Recent Short Interest
Express News | Alvotech SA - FDA Review Process Expected to Complete in Q4 2025
Express News | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for Avt05, a Proposed Biosimilar to Simponi® and Simponi Aria® (Golimumab)